These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36366293)

  • 21. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis.
    Farroni C; Picchianti-Diamanti A; Aiello A; Nicastri E; Laganà B; Agrati C; Castilletti C; Meschi S; Colavita F; Cuzzi G; Casetti R; Grassi G; Petrone L; Vanini V; Salmi A; Repele F; Altera AMG; Maffongelli G; Corpolongo A; Salemi S; Di Rosa R; Nalli G; Sesti G; Vaia F; Puro V; Goletti D
    Front Immunol; 2022; 13():846753. PubMed ID: 35309297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of COVID-19 mRNA vaccination in patients with autoimmune disorders: humoral and cellular immune response.
    Filippini F; Giacomelli M; Bazzani C; Fredi M; Semeraro P; Tomasi C; Franceschini F; Caruso A; Cavazzana I; Giagulli C
    BMC Med; 2023 Jun; 21(1):210. PubMed ID: 37316832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Term SARS-CoV-2-Specific Humoral and T Cell Responses after the BNT162b2 or BBIBP-CorV Booster and the Incidence of Breakthrough Infections among Healthcare Workers.
    Matula Z; Bekő G; Király V; Gönczi M; Zóka A; Baráth A; Uher F; Vályi-Nagy I
    Vaccines (Basel); 2023 Dec; 12(1):. PubMed ID: 38276662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccination strategy and anti - SARS-CoV-2 S titers in healthcare workers of the INT - IRCCS "Fondazione Pascale" Cancer Center (Naples, Italy).
    Cavalcanti E; Isgrò MA; Rea D; Di Capua L; Trillò G; Russo L; Botti G; Miscio L; Buonaguro FM; Bianchi AAM
    Infect Agent Cancer; 2021 May; 16(1):32. PubMed ID: 33980271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune response after two doses of the BNT162b2 COVID-19 vaccine and risk of SARS-CoV-2 breakthrough infection in Tyrol, Austria: an open-label, observational phase 4 trial.
    Seekircher L; Bánki Z; Kimpel J; Rössler A; Schäfer H; Falkensammer B; Bante D; Forer L; Schönherr S; ; Harthaller T; Sacher M; Ower C; Tschiderer L; Ulmer H; Krammer F; von Laer D; Borena W; Willeit P
    Lancet Microbe; 2023 Aug; 4(8):e612-e621. PubMed ID: 37354911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study.
    Moor MB; Suter-Riniker F; Horn MP; Aeberli D; Amsler J; Möller B; Njue LM; Medri C; Angelillo-Scherrer A; Borradori L; Radonjic-Hoesli S; Seyed Jafari SM; Chan A; Hoepner R; Bacher VU; Mani LY; Iype JM; Hirzel C; Maurer B; Sidler D
    Lancet Rheumatol; 2021 Nov; 3(11):e789-e797. PubMed ID: 34514436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complete (Humoral and Cellular) Response to Vaccination against COVID-19 in a Group of Healthcare Workers-Assessment of Factors Affecting Immunogenicity.
    Morgiel E; Szmyrka M; Madej M; Sebastian A; Sokolik R; Andrasiak I; Chodyra M; Walas-Antoszek M; Korman L; Świerkot J
    Vaccines (Basel); 2022 Apr; 10(5):. PubMed ID: 35632467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heterologous and homologous COVID-19 mRNA vaccination schemes for induction of basic immunity show similar immunogenicity regarding long-term spike-specific cellular immunity in healthcare workers.
    Wagenhäuser I; Almanzar G; Förg FB; Stein A; Eiter I; Reusch J; Mees J; Herzog A; Vogel U; Frey A; Lâm TT; Schubert-Unkmeir A; Dölken L; Kurzai O; Frantz S; Gabel A; Petri N; Prelog M; Krone M
    Vaccine; 2024 Aug; 42(21):126132. PubMed ID: 39034219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A 12-month follow-up of the immune response to SARS-CoV-2 primary vaccination: evidence from a real-world study.
    Fedele G; Schiavoni I; Trentini F; Leone P; Olivetta E; Fallucca A; Fiore S; Di Martino A; Abrignani S; Baldo V; Baldovin T; Bandera A; Clerici P; De Paschale M; Diaco F; Domnich A; Fortunato F; Giberti I; Gori A; Grifantini R; Lazzarotto T; Lodi V; Mastroianni CM; Prato R; Restivo V; Vitale F; Brusaferro S; Merler S; Palamara AT; Stefanelli P;
    Front Immunol; 2023; 14():1272119. PubMed ID: 38077369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod.
    Capuano R; Bisecco A; Conte M; Donnarumma G; Altieri M; Grimaldi E; Franci G; Chianese A; Galdiero M; Coppola N; Tedeschi G; Gallo A
    Mult Scler Relat Disord; 2022 Apr; 60():103724. PubMed ID: 35272145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Humoral and cell-mediated immune responses in HIV-vertically infected young patients after three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine.
    Vanetti C; Stracuzzi M; Crivellaro E; Ciciliano F; Garziano M; Fenizia C; Biasin M; Rubinacci V; Amendola A; Tanzi E; Zuccotti GV; Clerici M; Giacomet V; Trabattoni D
    Front Immunol; 2023; 14():1301766. PubMed ID: 38250079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study.
    Jyssum I; Kared H; Tran TT; Tveter AT; Provan SA; Sexton J; Jørgensen KK; Jahnsen J; Kro GB; Warren DJ; Vaage EB; Kvien TK; Nissen-Meyer LH; Anderson AM; Grødeland G; Haavardsholm EA; Vaage JT; Mjaaland S; Syversen SW; Lund-Johansen F; Munthe LA; Goll GL
    Lancet Rheumatol; 2022 Mar; 4(3):e177-e187. PubMed ID: 34977602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study.
    Mok CKP; Chen C; Zhao S; Sun Y; Yiu K; Chan TO; Lai HL; Lai KC; Lau KM; Ling KC; Chan KKP; Ng SS; Ko FW; Peiris M; Hui DS
    Lancet Microbe; 2023 Jun; 4(6):e418-e430. PubMed ID: 37086735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kinetics and persistence of cellular and humoral immune responses to SARS-CoV-2 vaccine in healthcare workers with or without prior COVID-19.
    Chivu-Economescu M; Bleotu C; Grancea C; Chiriac D; Botezatu A; Iancu IV; Pitica I; Necula LG; Neagu A; Matei L; Dragu D; Sultana C; Radu EL; Nastasie A; Voicu O; Ataman M; Nedeianu S; Mambet C; Diaconu CC; Ruta SM
    J Cell Mol Med; 2022 Feb; 26(4):1293-1305. PubMed ID: 35043552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of humoral and cellular immune responses in hematologic diseases following completed vaccination protocol with BBIBP-CorV, or AZD1222, or BNT162b2 vaccines against SARS-CoV-2.
    Szabó E; Modok S; Rónaszéki B; Faragó A; Gémes N; Nagy LI; Hackler L; Farkas K; Neuperger P; Balog JÁ; Balog A; Puskás LG; Szebeni GJ
    Front Med (Lausanne); 2023; 10():1176168. PubMed ID: 37529238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Persistence of Immune Response in Health Care Workers After Two Doses BNT162b2 in a Longitudinal Observational Study.
    Herzberg J; Fischer B; Lindenkamp C; Becher H; Becker AK; Honarpisheh H; Guraya SY; Strate T; Knabbe C
    Front Immunol; 2022; 13():839922. PubMed ID: 35309303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Humoral and T-Cell Mediated Response after the Third Dose of mRNA Vaccines in Patients with Systemic Lupus Erythematosus on Belimumab.
    Quartuccio L; De Marchi G; Domenis R; Cabas N; Guella S; Paradiso A; Fabro C; Beltrami AP; De Vita S; Curcio F
    J Clin Med; 2023 Jan; 12(3):. PubMed ID: 36769731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Humoral and cellular immune responses in fully vaccinated individuals with or without SARS-CoV-2 breakthrough infection: Results from the CoV-ADAPT cohort.
    Hollstein MM; Dierks S; Schön MP; Bergmann A; Abratis A; Eidizadeh A; Kaltenbach S; Schanz J; Groß U; Leha A; Kröger A; Andag R; Zautner AE; Fischer A; Erpenbeck L; Schnelle M
    J Med Virol; 2023 Oct; 95(10):e29122. PubMed ID: 37787583
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence of immune response to BNT162b2 COVID-19 vaccine in systemic lupus erythematosus patients treated with Belimumab.
    Schiavoni I; Olivetta E; Natalucci F; Olivieri G; Lo Presti A; Fedele G; Stefanelli P; Ceccarelli F; Conti F
    Lupus; 2023 Mar; 32(3):394-400. PubMed ID: 36607313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.